Valuation: GlaxoSmithKline plc

Market Cap 8.13TCr 11TCr 9.49TCr 8.86TCr 15TCr 10,34600Cr 16TCr 1,05100Cr 41TCr 5,11900Cr 41TCr 40TCr 17,69800Cr P/E 2026 *
12.8x
P/E 2027 * 11.8x
Enterprise Value 10TCr 14TCr 12TCr 11TCr 19TCr 13,07900Cr 20TCr 1,32800Cr 52TCr 6,47200Cr 51TCr 50TCr 22,37300Cr EV / Sales 2026 *
3.02x
EV / Sales 2027 * 2.63x
Free-Float
93.18%
Yield 2026 *
3.43%
Yield 2027 * 3.61%

Last Transcript: GlaxoSmithKline plc

Manager TitleAgeSince
Chief Executive Officer - 01/01/2026
Director of Finance/CFO 64 01/05/2023
Chief Tech/Sci/R&D Officer - 01/12/2021
Director TitleAgeSince
Director/Board Member - 06/05/2026
Director/Board Member 64 01/01/2018
Chairman 68 01/09/2019
Change 5-day change 1-year change 3-year change Capi.($)
-0.91%+4.53%+59.34%+167.45% 1,08900Cr
-0.50%+3.99%+58.12%+58.67% 64TCr
+0.11%+4.82%+38.85%+77.51% 47TCr
-1.69%+8.81%+39.38%+33.67% 36TCr
-0.51%+3.51%+36.97%+42.46% 30TCr
+1.50%+3.40%+17.71%+17.41% 27TCr
+0.79%+5.81%-2.55%-38.10% 23TCr
-1.39%+6.34%+28.23%+66.24% 21TCr
-0.76%+2.88%+17.39%+76.12% 17TCr
Average -0.22%+5.07%+32.61%+55.72% 41.46TCr
Weighted average by Cap. -0.33%+5.14%+42.46%+81.42%

Financials

2026 *2027 *
Net sales 3.4TCr 4.52TCr 3.97TCr 3.71TCr 6.37TCr 4,33000Cr 6.53TCr 44TCr 17TCr 2,14300Cr 17TCr 17TCr 7,40800Cr 3.56TCr 4.74TCr 4.16TCr 3.88TCr 6.67TCr 4,53600Cr 6.84TCr 46TCr 18TCr 2,24500Cr 18TCr 17TCr 7,75900Cr
Net income 656.82Cr 872.58Cr 766.74Cr 715.69Cr 1.23TCr 84TCr 1.26TCr 8.49TCr 3.32TCr 41TCr 3.28TCr 3.2TCr 1,43000Cr 692.22Cr 919.61Cr 808.06Cr 754.26Cr 1.3TCr 88TCr 1.33TCr 8.94TCr 3.5TCr 44TCr 3.45TCr 3.38TCr 1,50700Cr
Net Debt 2.15TCr 2.85TCr 2.51TCr 2.34TCr 4.02TCr 2,73300Cr 4.12TCr 28TCr 11TCr 1,35200Cr 11TCr 10TCr 4,67500Cr 1.25TCr 1.66TCr 1.46TCr 1.36TCr 2.34TCr 1,58700Cr 2.39TCr 16TCr 6.3TCr 79TCr 6.22TCr 6.09TCr 2,71500Cr
Logo GlaxoSmithKline plc
GSK plc is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (41.3%): intended mainly for HIV infection (57% of net sales), immune system disorders and respiratory diseases (28.3%), and cancer (14.7%); - OTC and parapharmaceutical medicine (30.7%); - vaccines (28%). Net sales are distributed geographically as follows: the United Kingdom (2.1%), Europe (21%), the United States (51.6%), and other (25.3%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-